言語を選択

IFN-beta

IFN-beta 詳細

英語名	Interferon beta	市販薬剤の数	1
治験薬の数	6	ターゲットの別称	Interferon Beta 1，Interferon， Beta 1， Fibroblast，IFNB，IFB，IFF，Interferon-beta，IFN-beta，Fibroblast interferon，IFNB1，Interferon beta
研究＆開発段階	Approved

英語名	Interferon beta
ターゲットの別称	Interferon Beta 1，Interferon， Beta 1， Fibroblast，IFNB，IFB，IFF，Interferon-beta，IFN-beta，Fibroblast interferon，IFNB1，Interferon beta
市販薬剤の数	1
治験薬の数	6
研究＆開発段階	Approved

IFN-beta 製品リスト

属性
Protein (3)
製品ライブラリ
オンライン (3)
種
Human (2)Mouse (1)
タグ
Fc Tag (1)His Tag & Avi Tag (2)
マーカー
Unconjugated (1)Biotin-labeled (2)

製品番号	種	発現システム	製品説明
IFB-H5254	Human	HEK293	Human IFN-beta Protein, Fc Tag (MALS verified)
IFB-H82E4	Human	HEK293	Biotinylated Human IFN-beta Protein, His,Avitag™ (MALS & SPR verified)
IFB-M82E3	Mouse	HEK293	Biotinylated Mouse IFN-beta Protein, His,Avitag™ (MALS & SPR verified)

総数量3

IFN-betaバックグランド

Human type I interferons (IFNs) are a large subgroup of interferon proteins that help regulate the activity of the immune system. Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The IFN-β proteins are produced in large quantities by fibroblasts. They have antiviral activity that is involved mainly in innate immune response. Two types of IFN-β have been described, IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate. Furthermore, IFN-β1 can bind to a IFNAR1-IFNAR2 heterodimeric receptor, and can also function with IFNAR1 alone and independently of Jak-STAT pathways.

IFN-beta分子の別称

IFNB1,Interferon beta,IFN-beta,IFB,IFNB

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Dazukibart	PF-06823859	Phase 3 Clinical	Pfizer Inc	Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Muscular Diseases; Myositis; Polymyositis	詳細
Peginterferon beta-1a (CinnaGen)		Phase 3 Clinical	Cinnagen	Multiple Sclerosis, Relapsing-Remitting	詳細
VSV-IFNbeta-NIS		Phase 2 Clinical	Vyriad	Angioimmunoblastic T-cell Lymphoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Histiocytoma; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	詳細
VSV-hIFNbeta-NIS (University of Tennessee)		Phase 1 Clinical	The University Of Tennessee	Endometrial Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Multiple Myeloma	詳細
MEM-288	MEM-288	Phase 1 Clinical	Memgen	Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	詳細
SCD-153	SCD-153	Phase 1 Clinical	Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University, Sun Pharma Advanced Research Company Ltd	Alopecia Areata	詳細